Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry

April W. Armstrong,Laura K. Ferris,Kristina Callis Duffin,Jud C. Janak,Adam P. Sima,Thomas Eckmann,Huzefa Photowala,Manish Patel,Vishvas Garg,Bruce E. Strober

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）

引用 0|浏览6

暂无评分

摘要

Introduction: Risankizumab, an interleukin 23 inhibitor, is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the long-term real-world eﬀectiveness of risankizumab in achieving the National Psoriasis Foundation (NPF)-defined treatment targets and maintenance of clinical response.

查看译文

关键词

severe psoriasis,risankizumab,skin,real-world,treat-to-target

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要